We talk with Amir Hayeri, founder and CEO of BioConscious Technologies, about using machine learning to predict glucose trends and turn CGM streams into actionable clinical foresight. We dig into accuracy, trust, liability, and why clustering dysglycemia may reveal risk that HbA1c can miss.

• Amir’s origin story and the prevention-first philosophy behind BioConscious
• Predicting glucose 60 minutes ahead using CGM data and how accuracy is measured
• Why an app without a clinical workflow has limited impact
• Population triage for clinics using clustering to surface high-risk patients fast
• Clinician concerns about liability and the fear of replacing doctors
• Building trust through explainable AI and a clear user interface
• Plans for studies and publication areas including gestational diabetes and dysglycemia
• The “glucose atlas” idea and what CGM can show in non-diabetic users
• Limits of mixing CGM with wearables data and why model complexity can hurt performance

In this episode in our Diabetes Technology Starts series, Lucas Schuster, founder and CEO of Syntactiq, unpacks the gap between what diabetes technology can measure and what research teams can realistically use day to day. We talk about collecting richer contextual data, enabling donation for research, and supporting partners who need to analyze their own sensitive health data, from continuous glucose monitoring logs to EHR datasets, omics data, and clinical trial data.

In the third episode of our Diabetes Technology Starts series, we talk with John Sjolund, co-founder of Luna Diabetes, about bringing nighttime automated insulin delivery to people who use pens, focusing on better mornings, fewer alarms, and simpler tech. We cover evidence so far, algorithm design, travel, Type 2 potential, cost, and environmental impact.